Egle Therapeutics
- Address
- 5 Rue Gardenat Lapostol
Sponsor Overview
Specializations
Advanced and Metastatic Solid Tumors
Clinical research at Egle Therapeutics includes advanced and/or metastatic solid tumors, with attention to anti-cancer immunotherapy and treatment approaches for unmet oncologic needs. The sponsor’s oncology portfolio centers on adult patients with selected solid malignancies.
- Solid tumor oncology
- Metastatic cancer
- Immune-based cancer treatment
- Pembrolizumab combination therapy
This area reflects interest in tumor response, safety, and tolerability within oncology-focused drug development.
Atopic Dermatitis and Autoimmune Disease
The sponsor also funds research in atopic dermatitis and broader autoimmune disease settings, indicating a therapeutic focus on inflammatory skin disease and immune dysregulation. This includes work involving adults with autoimmune conditions.
- Atopic dermatitis
- Autoimmune disorders
- Inflammatory dermatology
- Immune-mediated disease
These studies place emphasis on therapeutic modulation of the immune system in chronic inflammatory disease.
First-in-Human Clinical Development
Egle Therapeutics is active in first-in-human clinical research, supporting early clinical exploration of novel therapeutics in both oncology and autoimmune disease. The sponsored program includes adult populations in multiple therapeutic settings.
- Early-stage clinical development
- Novel biologic therapies
- Adult patient populations
- Translational medicine
This research activity spans human safety assessment and initial evaluation of therapeutic activity across distinct disease areas.
Immunotherapy and Immune Regulation
The sponsor’s trial portfolio highlights interest in immune checkpoint-based treatment and other immune-regulating therapies. Its research spans both cancer immunology and autoimmune biology, reflecting a focus on targeted manipulation of immune pathways.
- Immune checkpoint therapy
- Cancer immunology
- Autoimmune immunology
- Targeted immune modulation
These programs connect oncologic therapy with inflammation-driven disease through shared immunological mechanisms.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase I, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of EGL-003 in Healthy Volunteers and Adults with Atopic Dermatitis |  Bulgaria Germany Poland | Recruiting |
| Phase 1/2 Evaluation of EGL-001 Monotherapy and Combination with Anti-PD(L)-1 in Advanced/Metastatic Solid Tumors |  France Spain | Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 18 sites across their trial portfolio.
Therapeutic Focus
- 1.Not possible to specify1 trial220 other sponsors
- 2.Skin and Connective Tissue Diseases1 trial247 other sponsors
Partnered Research Centres
18 centres- Address
- Langenbeckstrasse 1, Oberstadt, 55131 Mainz
- Address
- 1 Rue Professeur Marion, 21000 Dijon
- Address
- Ul. Stacyjna 1/42, 53-613 Wroclaw
- Address
- ul. Klonowa 107/L7, 25-553 Kielce
- Address
- Spandauer Damm 130, 14050 Berlin
- Address
- Calle Marquesado De Santa Marta 1, 28027 Pamplona
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Egle Therapeutics.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.